Silcsbio LLC provides software and services for drug discovery. The company's core technology centers on a computer algorithm for drug discovery, which allows them to supply pharmaceutical companies with software and computational services enabling the identification and optimization of drug leads. The company's primary technology, Site Identification by Ligand Competitive Saturation (SILCS), was licensed from University of Maryland Ventures in 2013 and helped create the firm's first product line.
